Dancann Pharma

Jes Lunde brings a wealth of experience to the Company, having served as a Member of the Danish Parliament (Folketinget) from 1984 to 2001, representing the Socialist People’s Party (SF). During his tenure, he held prominent roles, including Group Chairman and Member of the Finance Committee.

​

Following his departure from Parliament and SF in 2001, Jes Lunde transitioned into high-level civil service, holding several key positions until 2021. These included serving as Director in the North Jutland County (Norjyllands Amt), Director in the Ministry of the Environment (Miljøministeriet), Director in Jammerbugt Municipality, and most recently, as Municipal Director (Kommunaldirektør) in Rebild Municipality.

In 2022, Jes Lunde was elected to the City Council in Aalborg, representing the Danish Social Liberal Party (Radikale Venstre). He has since served as Alderman (Rådmand) for Health and Culture and as a member of Aalborg Municipality’s Finance Committee. He has also represented Local Government Denmark (KL) as a member of its Health and Elderly Committee and acted as a lobbyist for KL in discussions with Danish Parliament health spokespersons.

Jes Lunde is currently the Chairman of the Board of Otiom A/S, a company specializing in intelligent tracking solutions designed to enhance safety for cognitively challenged individuals, caregivers, and relatives.

In his private life, Jes Lunde resides in North Jutland, where he owns an organic farm spanning 120 hectares, dedicated to grass, grain, and 50 hectares of natural land.

Carsten Trads, Chairman of DanCann Pharma, comments:

“The future of DanCann Pharma looks promising, as the Pilot Programme for medicinal cannabis moves toward the prospect of permanent legislation under the current Danish government. DanCann Pharma is already importing and distributing cannabinoid medicines and plans to launch additional medicinal cannabis products, as well as other cannabinoid-based solutions aimed at improving the well-being and quality of life for patients and their families.

DanCann Pharma operates within a dynamic political framework that is constantly evolving. We are excited about the potential election of Jes to our Board of Directors. His extensive knowledge, experience, and network within both national and municipal politics will enable DanCann Pharma to adapt more effectively and efficiently to the political frameworks that govern and evolve in our industry.”

Jes Lunde states: 

“DanCann Pharma is a dynamic company with a skilled and ambitious leadership team and organization.

DanCann Pharma’s mission, “Improving the health and life quality for patients with challenges,” is highly inspiring. I look forward to contributing to addressing the challenges encountered along the way in achieving this important goal. I am eager to apply my experience to support this effort, both in navigating the political landscape and in advancing the Company’s strategic initiatives.”

Jeppe Krog Rasmussen, CEO of DanCann Pharma, concludes:

“DanCann Pharma’s ultimate goal is to establish a sustainable company that makes a tangible difference for the patient groups we serve. Within our leadership and current Board of Directors, we already possess many of the competencies needed to develop and operate a sustainable business.

Jes will bring additional knowledge and experience, particularly in areas related to collaboration and dialogue with public systems and the political sphere. His expertise in public affairs and advocacy will be instrumental in advancing the interests of DanCann Pharma and its stakeholders.”

The Company will hold its Extraordinary General Meeting on 10 December 2024, during which Jes Lunde’s nomination to the Board of Directors will be presented for approval.

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm.

For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO

E-mail: jkr@dancann.com

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.